Clinical trials
1 active trial in Singapore
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)
Updated
Reviewed by Vidhi Upadhyay
Singapore Joint Health Supplements Market Industry Trends and Forecast to 2034: Segmented by (Ingredient, Form, Distribution Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$12.2 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $12.9 Mn | — | — |
| 2025 (base) | $13.8 Mn | +$0.9 Mn | — |
| 2026 (forecast) | $14.8 Mn | +$1.0 Mn | +7.3% |
| 2027 (forecast) | $15.9 Mn | +$1.1 Mn | +15.1% |
| 2028 (forecast) | $17.1 Mn | +$1.2 Mn | +23.5% |
| 2029 (forecast) | $18.3 Mn | +$1.2 Mn | +32.6% |
| 2030 (forecast) | $19.7 Mn | +$1.3 Mn | +42.2% |
| 2031 (forecast) | $21.1 Mn | +$1.4 Mn | +52.6% |
| 2032 (forecast) | $22.6 Mn | +$1.5 Mn | +63.8% |
| 2033 (forecast) | $24.3 Mn | +$1.7 Mn | +75.7% |
| 2034 (forecast) | $26.0 Mn | +$1.8 Mn | +88.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $13.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $26.0 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Ingredient, form and distribution channel (see all) |
| Key players | Bayer AG, Haleon PLC, Nature’s Bounty, Nestle, Pharmavite LLC (see all) |
| Regulator in Singapore | HSASource: Health Sciences Authority. Checked 14 Nov 2026.Source: Health Sciences Authority. Checked 14 Nov 2026. |
| Active clinical trials | 1 in SingaporeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Joint health supplements contain glucosamine, chondroitin, collagen and other ingredients marketed to ease stiffness and support joints.
Key segments of the joint Health Supplements market include ingredient (Glucosamine, Chondroitin and Collagen) and form (Tablets, Capsules and Powders).
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the joint Health Supplements market. Older adults and their families are spending more on staying active and independent.
Preventive care, personalised plans based on biomarkers and home-based services give the joint Health Supplements market room to grow, especially in fast-ageing countries in Asia and Europe.
Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the joint Health Supplements market.
The joint Health Supplements market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Therapeutic products need registration with the Health Sciences Authority (HSA).[1] Health supplements do not need approval from the Health Sciences Authority (HSA) before sale, but must not contain banned or harmful ingredients.[1] ClinicalTrials.gov lists 1 study on Joint Health Supplements that is recruiting, active or about to start in Singapore.[2] People aged 65 and over: 14.2% of people in 2025, the latest World Bank figure for Singapore.[3]
[1] Health Sciences Authority. Checked 14 Nov 2026.
[2] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.
Food and supplement rules, labelling and health-claim regulations govern joint Health Supplements products. Authorities such as the US FDA, EFSA and national food safety bodies set what can be sold and claimed in Singapore.
What doctors and scientists are doing in Joint Health Supplements right now, from free public sources.
1 active trial in Singapore
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)14.2 % of people
People aged 65 and over, Singapore, 2025 (World Bank).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.
From our blog
Singapore · 4 shared keywords
Singapore · 3 shared keywords
Singapore · 3 shared keywords
Singapore · 3 shared keywords
Singapore · 3 shared keywords
Singapore · 3 shared keywords
Digital Health · Singapore
Medical Devices · Singapore
Healthcare Services · Singapore
Digital Health · Singapore
Pharmaceuticals · Singapore
Medical Devices · Singapore